Ken Griffin Pacira Bio Sciences, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$11.7 - $28.46 $754,650 - $1.84 Million	64,500 Added 157.32%	105,500 $1.59 Million
Q2 2024 Aug 14, 2024	BUY	$25.5 - $31.51 $328,950 - $406,479	12,900 Added 45.91%	41,000 $1.17 Million
Q1 2024 May 15, 2024	BUY	$27.7 - $35.48 $77,560 - $99,343	2,800 Added 11.07%	28,100 $821,000
Q4 2023 Feb 14, 2024	BUY	$26.32 - $34.31 $607,992 - $792,561	23,100 Added 1050.0%	25,300 $853,000
Q3 2023 Nov 14, 2023	SELL	$30.68 - $40.09 $150,332 - $196,441	-4,900 Reduced 69.01%	2,200 $67,000
Q2 2023 Aug 14, 2023	SELL	$36.12 - $47.5 $307,020 - $403,750	-8,500 Reduced 54.49%	7,100 $284,000
Q1 2023 May 15, 2023	SELL	$35.53 - $43.38 $17,765 - $21,690	-500 Reduced 3.11%	15,600 $636,000
Q4 2022 Feb 14, 2023	SELL	$38.19 - $57.45 $332,253 - $499,815	-8,700 Reduced 35.08%	16,100 $621,000
Q3 2022 Nov 14, 2022	BUY	$51.24 - $58.89 $840,336 - $965,796	16,400 Added 195.24%	24,800 $1.32 Million

264

50.6M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $780M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.